Back

Cardiac structural and hemodynamic changes following cancer therapy in patients with hypertrophic cardiomyopathy

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Tian Zou

Mayo Clinic, Rochester (United States of America)

6 More presentations in this session

Presentation thumbnail
Baseline early diastolic mitral annular velocities and cancer therapy related cardiac dysfunction in HER2 therapy
Mr A. Chowdhury (Clayton, AU)
Abstract Slides
Presentation thumbnail
Incremental value of TAPSE added to HFA-ICOS for ESC-Defined Cancer Therapy–Related Cardiac Dysfunction
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence and severity of cancer-therapy-related cardiac dysfunction during contemporary breast cancer therapy in a real-world cohort
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Machine learning-driven probability of cancer therapy–related cardiac dysfunction in patients with non-Hodgkin lymphoma
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Agreement between manual and AI-enhanced echocardiographic assessment of cancer therapy-related cardiac dysfunction in patients with early breast cancer
Mr E. Orstad (Nordbyhagen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.
31 August 2024
thumbnail
Congress Presentation
A de novo systematic literature review to identify the clinical effectiveness and safety of different treatments for patients with non-obstructive hypertrophic cardiomyopathy
18 May 2025
thumbnail
Congress Presentation
Double jeopardy: pioneering inpatient therapy for obstructive hypertrophic cardiomyopathy in the oncologic setting
19 June 2026
thumbnail
Congress Presentation
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources